Needham Reiterates Buy on Personalis, Maintains $8 Price Target
Needham analyst Mike Matson reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8 price target.
Personalis Q4 EPS $(0.67) Misses $(0.64) Estimate, Sales $16.72M Beat $15.35M Estimate
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.64) by 4.69 percent. This is a 48.89 percent decrease over losses of $(0.45) per share from the
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
Needham has upgraded Personalis Inc (NASDAQ:PSNL) to Buy from Hold with a price target of $8. The analyst writes that Personalis’s cash…
Needham Upgrades Personalis to Buy, Announces $8 Price Target
Needham analyst Mike Matson upgrades Personalis (NASDAQ:PSNL) from Hold to Buy and announces $8 price target.
Why Personalis Shares Are Trading Higher Today
Personalis Inc (NASDAQ:PSNL) and Moderna Inc (NASDAQ:MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday’s pre-market session. The market value of their outstanding…
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Otonomy (NASDAQ:OTIC) shares increased by 19.1% to $0.21 during Thursday’s pre-market session. The company’s market cap stands…
Personalis And UCSF To Study Clinical Utility Of ctDNA For Treatment Response In Colorectal Cancer
Personalis, Inc. (NASDAQ:PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal